Evidence map›Paper›PMID 35481780›Full record

ArticleJournal of virology2022

Structural Insight into Molecular Inhibitory Mechanism of InsP

Yan Yang, Changhui Zhang, Xuehui Li, Li Li, Yanjuan Chen, Xin Yang, Yao Zhao, Cheng Chen, Wei Wang, Zhihui Zhong and 3 more

Open access · hybridAbstract readComment
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Hybrid genotype I and II ASFVEmerging microbes & infections · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Yan YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Changhui ZhangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Xuehui LiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Li LiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Yanjuan ChenState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Xin YangInstitute of Life Sciences, Chongqing Medical Universitygrid.203458.8, Chongqing, People's Republic of China.
Yao ZhaoShanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai, China.
Cheng ChenSchool of Life Sciences, Tianjin Universitygrid.33763.32, Tianjin, People's Republic of China.
Wei WangInstitute of Life Sciences, Chongqing Medical Universitygrid.203458.8, Chongqing, People's Republic of China.
Zhihui ZhongState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Cheng YangState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.
Zhen HuangCollege of Life Sciences, Sichuan Universitygrid.13291.38, Chengdu, China.
Dan SuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan Universitygrid.13291.38 and Collaborative Innovation Center of Biotherapy, Chengdu, Sichuan, People's Republic of China.ORCID 0000-0002-1059-5226
Sichuan University · CNChongqing Medical University · CNShanghaiTech University · CNTianjin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Removal of 5' cap on cellular mRNAs by the African swine fever virus (ASFV) decapping enzyme g5R protein (g5Rp) is beneficial to viral gene expression during the early stages of infection. As the only nucleoside diphosphate-linked moiety X (Nudix) decapping enzyme encoded in the ASFV genome, g5Rp works in both the degradation of cellular mRNA and the hydrolyzation of the diphosphoinositol polyphosphates. Here, we report the structures of dimeric g5Rp and its complex with inositol hexakisphosphate (InsP

Indexed as

African Swine Fever VirusEndoribonucleasesPhytic AcidAfrican Swine FeverAnimalsRNA, MessengerSwineEndoribonucleasesmRNA decapping enzymesPhytic AcidRNA, MessengerASFVg5RpInsP6mRNA-decapping enzymeNudix hydrolases

Identifiers

PMID35481780
PMCPMC9131872
OpenAlexW4226280006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.